In light of recent decisions by several pharmaceutical companies to pause, scale back, or discontinue their haemophilia gene therapy programs, the International Society on Thrombosis and Haemostasis (ISTH), the World Federation of Hemophilia (WFH), and the European Association for Haemophilia and Allied Disorders (EAHAD) have issued a formal Call-to-Action.
The statement highlights the importance of sustained innovation in haemophilia treatment, equitable and global access to all effective therapies, and continued collaboration among industry, regulators, researchers, payors, and the patient community.
Read the full statement here: https://www.isth.org/news/699516/